Oral Iron Supplementation in Pulmonary Hypertension
| Status: | Completed |
|---|---|
| Conditions: | High Blood Pressure (Hypertension) |
| Therapuetic Areas: | Cardiology / Vascular Diseases |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 2/4/2013 |
| Start Date: | January 2012 |
| End Date: | July 2012 |
| Contact: | Erika L Lundgrin, BA |
| Email: | lundgre@ccf.org |
| Phone: | 216-445-1756 |
The purpose of this study is to investigate the effects of iron supplementation in patients
with pulmonary arterial hypertension and iron deficiency.
Pulmonary arterial hypertension (PAH) is a chronic disease associated with upregulation of
hypoxia inducible-factor-1alpha (HIF-1alpha) and functional iron deficiency. The
investigators are proposing a prospective, single-arm, open-label intervention to determine
whether oral iron supplementation in patients with pulmonary arterial hypertension reduces
markers of HIF activation and improve clinical parameters of disease. After the baseline
visit, patients will be given ferrous sulfate tablets to take orally for 3 months. Outcome
data will be collected at the baseline visit and at the end of the 3-month study period.
Inclusion Criteria:
- age 21 and older
- diagnosis of idiopathic pulmonary arterial hypertension
- iron deficiency (transferrin saturation <20% and serum ferritin < 100 ug/l)
Exclusion Criteria:
- active infection, malignancy, or bleeding
- hemochromatosis
- chronic inflammatory or autoimmune disease
- currently taking experimental/study medications, erythropoietin, iron
supplementation, or immunosuppressants
- allergy to iron
We found this trial at
1
site
Cleveland Clinic Foundation The Cleveland Clinic (formally known as The Cleveland Clinic Foundation) is a...
Click here to add this to my saved trials
